NCNA VS AGE Stock Comparison

Performance

NCNA
10/100

NCNA returned -59.09% in the last 12 months. Based on SPY's performance of 11.53%, its performance is below average giving it a score of 10 of 100.

AGE
100/100

AGE returned 1.69% in the last 12 months. Based on SPY's performance of -13.31%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

NCNA
94/100

4 analysts offer 12-month price targets for NCNA. Together, they have an average target of 0, the most optimistic target put NCNA at 0 within 12-months and the most pessimistic has NCNA at 0.

AGE

"Analyst Price Targets" not found for AGE

Sentiment

NCNA
65/100

NCNA had a bullish sentiment score of 65.09% across Twitter and StockTwits over the last 12 months. It had an average of 2.33 posts, 1.33 comments, and 2.58 likes per day.

AGE

"Sentiment" not found for AGE

Technicals

NCNA
11/100

NCNA receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

AGE
14/100

AGE receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

Earnings

NCNA
10/100

NCNA has missed earnings 7 times in the last 20 quarters.

AGE

"Earnings" not found for AGE

Profit

NCNA
10/100

Out of the last 20 quarters, NCNA has had 0 profitable quarters and has increased their profits year over year on 0 of them.

AGE
10/100

Out of the last 20 quarters, AGE has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

NCNA
54/100

NCNA has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

AGE
47/100

AGE has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.

All score calculations are broken down here to help you make more informed investing decisions

NuCana plc American Depositary Share Summary

Nasdaq / NCNA

Healthcare

Biotechnology

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

AgeX Therapeutics, Inc. Summary

Healthcare

Biotechnology

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.

Power up your portfolio